Medicines List

The product has not yet been released on the market.

Description

Dapagliflozin Tchaikapharma contains the active substance dapagliflozin. It belongs to a group of medicines called “sodium glucose co-transporter-2 (SGLT2) inhibitors”. They work by blocking the SGLT2 protein in your kidney. By blocking this protein, blood sugar (glucose), salt (sodium) and water are removed from your body via the urine.

Indications

Dapagliflozin Tchaikapharma is used:

• in adults and children for the treatment of type 2 diabetes mellitus as an adjunct to diet and physical activity:
• as monotherapy when the use of metformin is considered inappropriate due to intolerance;
• as an add-on to other medicinal products for the treatment of type 2 diabetes mellitus;
• in adults for the treatment of symptomatic chronic heart failure;
• in adults for the treatment of chronic kidney disease.

Subject to medical prescription.

Concentration and pharmaceutical form: 10 mg film-coated tablets

The product has not yet been released on the market.

Description

Dapagliflozin/Metformin Tchaikapharma contains two different substances called dapagliflozin and metformin. Both belong to a group of medicines called “oral anti-diabetics”. These are medicines taken by mouth to treat diabetes.

Dapagliflozin/Metformin Tchaikapharma is used for a type of diabetes called “type 2 diabetes” in adult patients (aged 18 years and older) and usually occurs when you are older. If you have type 2 diabetes, your pancreas does not produce enough insulin or your body is not able to use the insulin it produces properly. This leads to a high level of sugar (glucose) in your blood.

• Dapagliflozin works by removing excess sugar from your body via your urine and lowers the amount of sugar in your blood. It can also help prevent heart disease.
• Metformin works mainly by inhibiting glucose production in the liver.

Indications

Dapagliflozin/Metformin Tchaikapharma is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise:

• in patients insufficiently controlled on their maximally tolerated dose of metformin alone;
• in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products;
• in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.

Subject to medical prescription.

Concentration and pharmaceutical form: 5 mg /850 mg; 5 mg /1000 mg film-coated tablets

The product has not yet been released on the market.

Description

Calisa contains two active ingredients, bisoprolol fumarate and ramipril in one capsule:
Ramipril is an angiotensin converting enzyme (ACE) inhibitor. It works by widening the blood vessels, which makes it easier for your heart to pump blood through them.
Bisoprolol fumarate belongs to a group of medicine called beta-blockers. Beta-blockers slow down the heart rate and make the heart more efficient at pumping blood around the body.

Indications

Calisa is used to treat high blood pressure (hypertension) and/or chronic heart failure with left heart chamber dysfunction (a condition where the heart is unable to pump enough blood to meet the body’s needs resulting in breathlessness and swelling) and/or to reduce the risk of cardiac events, such as heart attack, in patients with chronic coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) and who have already had a heart attack and/or an operation to improve the blood supply to the heart by widening the vessels that supply it, or diabetes with at least one cardiovascular risk factor.

 Subject to medical prescription.

 Concentration and pharmaceutical form: 5 mg/2.5 mg; 5 mg/5 mg; 10 mg/5 mg; 10 mg/10 mg hard capsules

The product has not yet been released on the market.

Description

Eltrombopag Tchaikapharma contains eltrombopag, which belongs to a group of medicines called thrombopoietin-receptor antagonists. It is used to help increase the number of platelets in your blood. Platelets are blood cells that help to reduce or prevent bleeding.

Indications

Eltrombopag Tchaikapharma is used to treat a bleeding disorder called immune (primary) thrombocytopenia (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked.

Eltrombopag Tchaikapharma can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment.

Subject to medical prescription.

Concentration and pharmaceutical form: 25 mg film-coated tablets